Health Catalyst, Inc. (HCAT)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
$1.69-1.17%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
QuarterlyIQ Insights · HCAT
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On August 6, 2026, Health Catalyst, Inc. (the “Company”) issued a press release relating to its financial results for the quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended…
above. Concurrently with the closing of the Disposition, Health Catalyst and the Buyer entered into a transition services agreement pursuant to which Health Catalyst agreed to provide certain transition services related to VitalWare for specified periods of up to six months following the closing of the Disposition. The foregoing description of the Disposition and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the Purchase…
above are filed as Exhibit 99.3 to this Current Report on Form 8-K and incorporated herein by reference: • Health Catalyst’s unaudited pro forma condensed consolidated balance sheets as of June 30, 2026; • Health Catalyst’s unaudited pro forma condensed consolidated statement of operations for the six months ended June 30, 2026; • Health Catalyst’s unaudited pro forma condensed consolidated statement of operations for the year ended December 31, 2025; and • Notes to the unaudited pro forma co…
of Health Catalyst’s Current Report on Form 8-K filed on July 18, 2024, and are incorporated into this
Entry into a Material Definitive Agreement. On June 4, 2026, Health Catalyst, Inc. ("Health Catalyst") entered into a Unit Purchase Agreement (the "Purchase Agreement") with Med-Metrix, LLC ("Buyer"), pursuant to which, among other things, Health Catalyst has agreed to sell all of the equity interests of Vitalware, LLC, through which Health Catalyst conducts its Vitalware business (the "Vitalware Business"), to Buyer (the "Transaction"). In connection with the Transaction, Health Catalyst wil…
shall not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference into any filing of Health Catalyst, whether made before or after the date hereof, regardless of any general incorporation language in such filing. Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking statements” within the me…
Results of Operations and Financial Condition. On May 11, 2026 , Health Catalyst, Inc. (the “Company”) issued a press release relating to its financial results for the quarter ended March 31, 2026 . A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amende…
Board Member — Steven Nelson: Steven Nelson was appointed to the Board of Directors as a new member.
Other Events. As part of Project Nexus, a strategic initiative designed to fundamentally transform the Company's operating model, simplify its organizational structure, and align resources around its highest-conviction technology opportunities, our Board authorized a workforce reduction on April 24, 2026. The Company expects this initiative to reduce its global workforce by approximately 9% and eliminate approximately 100 additional open, budgeted headcount positions across the US and India,…
Chief People Officer — Linda Llewelyn: The role of Chief People Officer was eliminated due to a workforce reduction.
Chief Executive Officer — Daniel Burton: Daniel Burton retired as CEO and will serve as a strategic advisor until December 31, 2026.
Results of Operations and Financial Condition. On March 12, 2026, Health Catalyst, Inc. (the Company) issued a press release relating to its financial results for the quarter and year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…
of this Form 8-K, including the information contained in Exhibit 99.1 of this Form 8-K, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Forward-Looking Statements…
CEO — Ben Albert: Dan Burton retired as CEO and Ben Albert was appointed as the new CEO and Director.
Chief Commercial Officer — Kevin Freeman: Kevin Freeman will cease to serve as Chief Commercial Officer but will transition into a senior advisor role.
Results of Operations and Financial Condition. On January 12, 2026, Health Catalyst, Inc. (the “Company”) published certain preliminary unaudited estimated 2025 financial and operational results and forward-looking commentary (“Excerpt”). These preliminary unaudited estimated results are subject to change upon completion of the Company’s accounting and annual audit procedures and are therefore subject to adjustment. Additional information and disclosures would be required for a more complete…
Director — Matthew Kolb: Mr. Kolb agreed not to stand for re-election at the Company’s 2026 annual meeting of stockholders.
The foregoing summary of the letter agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the letter agreement, a copy of which is attached as Exhibit 10.1 and is incorporated herein by reference.
Results of Operations and Financial Condition. On November 10, 2025, Health Catalyst, Inc. (the “Company”) issued a press release relating to its financial results for the quarter ended September 30, 2025. A copy of the press release and the Q3 2025 earnings release summary are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are each incorporated herein by reference. The foregoing information (including Exhibits 99.1 and 99.2 attached hereto) is being furnished and shall n…
President and Chief Operating Officer — Benjamin Albert: Benjamin Albert was promoted to President and Chief Operating Officer.
of this Current Report on Form 8-K, including the information contained in Exhibit 99.1 of this Current Report on Form 8-K, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such…
Results of Operations and Financial Condition. On May 7, 2025 , Health Catalyst, Inc. (the “Company”) issued a press release relating to its financial results for the quarter ended March 31, 2025 . A copy of the press release and the Q1 2025 earnings release summary are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are each incorporated herein by reference. The foregoing information (including Exhibits 99.1 and 99.2 attached hereto) is being furnished and shall not be de…
Results of Operations and Financial Condition. On February 26, 2025, Health Catalyst, Inc. (the Company) issued a press release relating to its financial results for the quarter and year ended December 31, 2024. A copy of the press release and the summary of the Company's 2024 Financial Highlights, 2025 Guidance & Key Themes are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and each are incorporated herein by reference. The foregoing information (including the exhibits set f…
Director — Anita Pramoda: Ms. Pramoda resigned from the Board and her resignation is not due to any disagreement or conflict with the Company.
Unregistered Sales of Equity Securities. The information set forth in
Importance-ranked changes since the prior daily snapshot.
Signal changed from 'mixed' to 'cautious'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.